Business
AMGEN ANNOUNCES NEW OTEZLA (APREMILAST) DATA AT AAD CONGRESS 2022
New data further reinforces clinical benefit of Otezla in mild to moderate plaque psoriasis and in patients with palmoplantar pustulosis Real-world evidence
About this update from Amgen Inc.
[{"type":"text","content":"New data further reinforces clinical benefit of Otezla in mild to moderate plaque psoriasis and in patients with palmoplantar pustulosis\nReal-world evidence data being presented demonstrates continued burden of disease for patients with mild to moderate plaque psoriasis\nOtezla is the first and only oral therapy FDA approved in adult patients with plaque psoriasis across all severities, including mild, moderate and severe\nTHOUSAND OAKS, Calif., March 25, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that new Otezla (apremilast) data, along with findings on the unmet need for patients with plaque psoriasis, will be presented at the American Academy of Dermatology (AAD) congress in Boston, Massachusetts, March 25-29, 2022. These data presentations follow the recent U.S. Food and Drug Administration (FDA) expanded Otezla label approval in December 2021.\n\"The data being presented at AAD demonstrates Amgen's continued commitment to supporting patients that are living with plaque psoriasis – especially those affected in difficult-to-treat areas as well as those with palmoplantar pustulosis – and understanding the unmet needs they continue to face,\" said Primal Kaur, vice president, Global Development, Inflammation at Amgen. \"With Otezla's recently expanded label that enables us to reach plaque psoriasis patients across all levels of disease severity, Amgen is now able to offer a treatment that could help to alleviate the significant burden on these patients\"\nAmgen will present data from a Phase 2 palmoplantar pustulosis (PPP) Japanese trial (PPP-001) as well as data from both the PROMINENT and ADVANCE Phase 3 studies in patients with mild to moderate plaque psoriasis. Results from the PPP-001 trial showed that apremilast demonstrated meaningful and early improvements in PPP severity, itching and pain, and that adverse events (the most common including gastrointestinal events and headache) were consistent with the known safety profile. The PROMINENT and ADVANCE studies reinforced the efficacy of apremilast in patients with mild to moderate plaque psoriasis.\nAdditionally, results from the multinational UPLIFT survey and real-world CorEvitas' Psoriasis registry continue to highlight the ongoing impact and unmet needs in patients with mild to moderate plaque psoriasis especially those with special area involvement. Bo...